Leqembi® Pen subcutaneous formulation approved in Japan

RegulatoryapprovedLeqembiPositive

AI Analysis

Summary

Eisai announced approval of Leqembi Pen, a subcutaneous autoinjector formulation, in Japan as a new route of administration for early Alzheimer's disease treatment. BioArctic AB is the partner on the development.

Outcome Details

Subcutaneous autoinjector formulation (Leqembi Pen) approved as new route of administration in Japan

Importance:7/10

Sentiment:

0.80

Regulatory ApprovalJapanNew FormulationSubcutaneousAlzheimer's Disease

Related Companies

$BIOA-B.ST $ESALY

Read the original article

Published by PR Newswire Pharma on September 16, 2026 6:15 AM

Read Original